Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 62 citing articles:

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Delphine Planas, David Veyer, Artem Baidaliuk, et al.
Nature (2021) Vol. 596, Iss. 7871, pp. 276-280
Open Access | Times Cited: 2013
SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India
Sarah Cherian, Varsha Potdar, Santosh Jadhav, et al.
Microorganisms (2021) Vol. 9, Iss. 7, pp. 1542-1542
Open Access | Times Cited: 628
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants
Jianying Liu, Yang Liu, Hongjie Xia, et al.
Nature (2021) Vol. 596, Iss. 7871, pp. 273-275
Open Access | Times Cited: 357
Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants
Matthew McCallum, Alexandra C. Walls, Kaitlin R. Sprouse, et al.
Science (2021) Vol. 374, Iss. 6575, pp. 1621-1626
Open Access | Times Cited: 285
Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
Delphine Planas, David Veyer, Artem Baidaliuk, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Closed Access | Times Cited: 278
SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants
Daniel Martínez-Flores, Jesús Zepeda–Cervantes, Adolfo Cruz-Reséndiz, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 211
COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies
Renuka Raman, Krishna Patel, Kishu Ranjan
Biomolecules (2021) Vol. 11, Iss. 7, pp. 993-993
Open Access | Times Cited: 166
Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections
Timothy Farinholt, HarshaVardhan Doddapaneni, Xiang Qin, et al.
BMC Medicine (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 162
Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis
Angel Yun-Kuan Thye, Jodi Woan‐Fei Law, Priyia Pusparajah, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1303-1303
Open Access | Times Cited: 120
Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 Cases in Houston, Texas
Paul A. Christensen, Randall J. Olsen, Sheng Long, et al.
American Journal Of Pathology (2021) Vol. 192, Iss. 2, pp. 320-331
Open Access | Times Cited: 110
Transmission dynamics and epidemiological characteristics of SARS-CoV-2 Delta variant infections in Guangdong, China, May to June 2021
Min Kang, Hualei Xin, Jun Yuan, et al.
Eurosurveillance (2022) Vol. 27, Iss. 10
Open Access | Times Cited: 98
Transmission dynamics and epidemiological characteristics of Delta variant infections in China
Min Kang, Hualei Xin, Jun Yuan, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 78
Potency of BNT162b2 and mRNA‐1273 vaccine‐induced neutralizing antibodies against severe acute respiratory syndrome‐CoV‐2 variants of concern: A systematic review of in vitro studies
Maryam Noori, Seyed Aria Nejadghaderi, Shahnam Arshi, et al.
Reviews in Medical Virology (2021) Vol. 32, Iss. 2
Open Access | Times Cited: 73
SARS-CoV-2 new variants: Characteristic features and impact on the efficacy of different vaccines
Abbas Khan, Taimoor Ashraf Khan, Shughla Ali, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 143, pp. 112176-112176
Open Access | Times Cited: 71
Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough infections
Timothy Farinholt, HarshaVardhan Doddapaneni, Xiang Qin, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 61
Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants
Matthew McCallum, Alexandra C. Walls, Kaitlin R. Sprouse, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 52
Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants
Deepali Gupta, Priyanka Sharma, Mandeep Singh, et al.
Cellular and Molecular Life Sciences (2021) Vol. 78, Iss. 24, pp. 7967-7989
Open Access | Times Cited: 51
An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era
Alejandro Pascual‐Iglesias, Javier Cantón, Ana María Ortega-Prieto, et al.
Pathogens (2021) Vol. 10, Iss. 8, pp. 1030-1030
Open Access | Times Cited: 45
Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas
Paul Christensen, Randall J. Olsen, S. Wesley Long, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 43
Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics
Lennox Chitsike, Penelope J. Duerksen-Hughes
Virology Journal (2021) Vol. 18, Iss. 1
Open Access | Times Cited: 41
In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike Protein
Nabarun Chandra Das, Pritha Chakraborty, Jagadeesh Bayry, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 35
Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody
Jonathan L. Torres, Gabriel Ozorowski, Emanuele Andreano, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 20
Open Access | Times Cited: 35
Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion
Wenlin Ren, Xiaohui Ju, Mingli Gong, et al.
mBio (2022) Vol. 13, Iss. 2
Open Access | Times Cited: 28
SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
Daniele Focosi, Marco Tuccori, Andreina Baj, et al.
Viruses (2021) Vol. 13, Iss. 7, pp. 1211-1211
Open Access | Times Cited: 38
SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera
Alona Kuzmina, Seraj Wattad, Yara Khalaila, et al.
iScience (2021) Vol. 24, Iss. 12, pp. 103467-103467
Open Access | Times Cited: 30
Page 1 - Next Page

Scroll to top